Diphenhydramine Hydrochloride

• A phase 2 study to research the safety and efficacy of datopotamab deruxtecan for non-squamous non-small cell lung cancer patients with acti… Not authorised
  2024-512369-14-00 Phase II 2 countries Medica Scientia Innovation Research S.L.
• POSITRON - PsilOcybin with pSychologIcal supporT foR cOcaiNe: a randomised controlled pilot feasibility trial of psilocybin with psychologic… Pending
  2024-515147-32-02 Phase II 1 country Trinity College Dublin
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
• A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myelom… Pending
  2025-522776-93-00 Phase I 1 country Regeneron Pharmaceuticals Inc.
• PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR… Pending
  2025-524613-89-00 Phase I/II 1 country Medica Scientia Innovation Research S.L.
• A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma Recruiting
  2023-505775-70-00 Phase II 6 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting
  2022-500266-10-00 Phase III 12 countries Rheacell GmbH & Co. KG
• Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients with Danon Disease Recruiting
  2023-506480-34-00 Phase II 2 countries Rocket Pharmaceuticals Inc.
• A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie… Recruiting
  2023-505242-25-00 Phase II 6 countries Regeneron Pharmaceuticals Inc.
• A Trial to Learn if Linvoseltamab is Safe and Works in Adults with Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Recruiting
  2023-507809-34-00 Phase I/II 2 countries Regeneron Pharmaceuticals Inc.
• Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting
  2022-501997-20-00 Phase I (FiH) 3 countries Moderna Inc.
• Ketamine study Recruiting
  2024-519097-39-01 Phase III 1 country Medical University Of Vienna
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Recruiting
  2024-511454-45-00 Phase I (FiH) 2 countries Regeneron Pharmaceuticals Inc.
• A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 Ended
  2023-509338-21-00 Phase II 3 countries Pfizer Inc.
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T… Ended
  2022-501346-30-00 Phase III 12 countries Celgene Corp.
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended
  2023-506515-18-00 Phase III 11 countries F. Hoffmann-La Roche AG
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended
  2023-506467-34-00 Phase III 10 countries F. Hoffmann-La Roche AG
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Rela… Ended
  2023-507313-94-00 Phase II 2 countries F. Hoffmann-La Roche AG
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended
  2023-505980-36-00 Phase III 9 countries F. Hoffmann-La Roche AG
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended
  2023-506429-13-00 Phase III 7 countries F. Hoffmann-La Roche AG
• Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to… Ended
  2022-503066-74-00 Phase I (FiH) 5 countries Bioinvent International AB
• A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended
  2023-506543-41-00 Phase III 14 countries F. Hoffmann-La Roche AG
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended
  2023-506641-35-00 Phase II 4 countries Kite Pharma Inc.

Showing 1–23 of 23 trials